Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
39.36
+0.24 (0.61%)
Apr 8, 2026, 9:29 AM HKT
Market Cap238.28B +113.6%
Revenue (ttm)16.72B +22.6%
Net Income6.18B +27.1%
EPS1.03 +26.4%
Shares Out6.05B
PE Ratio38.07
Forward PE34.83
Dividend0.43 (1.10%)
Ex-Dividend DateJul 3, 2026
Volume20,172,507
Average Volume11,244,767
Open37.88
Previous Close39.36
Day's Range37.04 - 39.40
52-Week Range19.82 - 44.22
Beta0.53
RSI70.67
Earnings DateMar 29, 2026

About HKG:3692

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei... [Read more]

Sector Healthcare
Founded 1995
Employees 9,313
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3692
Full Company Profile

Financial Performance

In 2025, HKG:3692's revenue was 15.03 billion, an increase of 22.57% compared to the previous year's 12.26 billion. Earnings were 5.56 billion, an increase of 27.07%.

Financial numbers in CNY Financial Statements